Mrs Athena Marie Duenas, LPC, CSAC III, ICADC | |
137 Nika Ln, Dededo, GU 96929-6008 | |
(671) 475-5440 | |
Not Available |
Full Name | Mrs Athena Marie Duenas |
---|---|
Gender | Female |
Speciality | Counselor - Professional |
Location | 137 Nika Ln, Dededo, Guam |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1063294585 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YP2500X | Counselor - Professional | LPC-151 (Guam) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Athena Marie Duenas, LPC, CSAC III, ICADC 137 Nika Ln, Dededo, GU 96929-6008 Ph: (671) 483-5150 | Mrs Athena Marie Duenas, LPC, CSAC III, ICADC 137 Nika Ln, Dededo, GU 96929-6008 Ph: (671) 475-5440 |
News Archive
State organizers are creating obstacles to national health care reform. In Colorado, Republican organizer Jon Caldara has vowed to derail national reforms with a ballot initiative. The Wall Street Journal reports about similar steps being taken across the country. "Republican attorneys general and governors ... are threatening to file suit to block a particular provision of the Senate bill that gives a special financial deal to Nebraska.
Ensysce Biosciences Inc. announced today the publication of their latest data on their delivery platform for short interfering RNA (siRNA) for therapeutic purposes in the journal Materials.
Grégoire Courtine doesn't hesitate to use the word "revolutionary" when describing the emerging field of optogenetics – a technology that uses pulses of light to control individual neural activity – and what it could mean for neuroscience. Courtine, director of the NeuroRestore research center (with neurosurgeon Jocelyne Bloch), is currently developing an optogenetic implant together with Stéphanie Lacour, who holds the Bertarelli Foundation Chair in Neuroprosthetic Technology.
The Food and Drug Administration (FDA) announced today the approval of Januvia (sitagliptin phosphate) Tablets, the first diabetes treatment approved in a new class of drugs known as DDP-4 inhibitors that enhances the body's own ability to lower elevated blood sugar.
› Verified 1 days ago
Ms. Joleen Aguon Baza, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 655 Harmon Loop Rd Ste 108, Dededo, GU 96929 Phone: 671-486-0287 |